SIM 0708
Alternative Names: SIM-0708Latest Information Update: 02 Sep 2026
At a glance
- Originator Simcere Pharmaceutical Group
- Class Anti-inflammatories; Antiasthmatics; Drug conjugates; Glucocorticoids; Immunoconjugates; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease
Most Recent Events
- 01 Nov 2023 SIM 0708 is available for licensing as of 01 Nov 2023. https://en.simcere.com/kfhz/kfhz.aspx
- 01 Nov 2023 Preclinical trials in Asthma in China (SC) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)
- 01 Nov 2023 Preclinical trials in Atopic dermatitis in China (SC) prior to November 2023 (Simcere Pharmaceutical Group pipeline, November 2023)